 Home > Active Ingredient News > Antitumor Therapy > ASCO 2021: Summary Overview and Outlook 19 | Overview of Latest Breast Cancer Research (Triple Negative Breast Cancer Column)

ASCO 2021: Summary Overview and Outlook 19 | Overview of Latest Breast Cancer Research (Triple Negative Breast Cancer Column)

 Last Update: 2021-06-04
 Source: Internet
 Author: User

Tags

45 16 simplified

what 5 htp

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The annual meeting of the American Society of Clinical Oncology (ASCO) will be held from June 4 to 8, 2021.
Many top research results at home and abroad will be announced soon.
Before the opening of the conference, scientists have begun to announce plans for clinical research abstracts and reports.
Metz Medicine will continue to pay attention to and report on academic highlights, and share them with fellow colleagues.
The annual meeting of the American Society of Clinical Oncology (ASCO) will be held from June 4 to 8, 2021.
Many top research results at home and abroad will be announced soon.
Before the opening of the conference, scientists have begun to announce plans for clinical research abstracts and reports.
Metz Medicine will continue to pay attention to and report on academic highlights, and share them with fellow colleagues.

Summary of breast cancer topics:

Breast topic summary: breast cancer topics Summary:Breast Cancer

ASCO 2021: Summary Overview and Outlook 19 | Overview of the Latest Research on Breast Cancer (Triple Negative Breast Cancer Column)

ASCO 2021: Summary Overview and Outlook 15 | Overview of Latest Breast Cancer Research (ER Positive Breast Cancer Column)

ASCO 2021: Summary Overview and Outlook 11 | Breast Cancer Research Overview (Invasive Breast Cancer Column)
ASCO 2021: Abstract Overview and Outlook 10 | Breast Cancer Research Overview (Triple Negative Breast Cancer Column)
ASCO 2021: Abstract Overview and Outlook 8 | Overview of the latest breast cancer research (male breast cancer column)

A multicenter randomized study of pembrolizumab/carboplatin and carboplatin alone in the treatment of patients with breast cancer and chest wall disease: TBCRC 044

1.
A multicenter randomized study of pembrolizumab/carboplatin and carboplatin alone in the treatment of patients with breast cancer and chest wall disease: TBCRC 044

Chest wall recurrence is a difficult-to-treat subtype of breast cancer and is associated with a short response time to treatment and an increased risk of distant metastasis.

Given the inflammatory nature of this disease and the association of chest wall disease with lymphatic vascular invasion, which is associated with higher programmed cell death 1 (PD-1) expression, we hypothesized that immunotherapy may be a beneficial treatment.
The combination of immunotherapy and chemotherapy has a synergistic effect and shows efficacy in the treatment of metastatic triple negative breast cancer (TNBC).

Chest wall recurrence is a difficult-to-treat subtype of breast cancer and is associated with a short response time to treatment and an increased risk of distant metastasis.

This is a multi-center, 2:1 randomized phase II study in which pembrolizumab/carboplatin (group A, 56 patients) and carboplatin (group B) were performed in 84 patients with breast cancer and chest wall disease.

For details see: Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044 For details see: For details see:Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044

Breast cancer (BC) exhibits a naive and capable immune system in the early stage.

Most of the characteristics of the two queues are balanced.

The benefits of DCV seem to be prominent in PD-L1-negative tumors with a proper environment for basic immunity.

：Impact of dendritic cell vaccines added to neoadjuvant CT on pathological complete responses in early breast cancer patients according to PD-L1 expression：：Impact of dendritic cell vaccines added to neoadjuvant CT on pathological complete responses in early breast cancer patients according to PD-L1 expression

，（TNBC）。，TNBC。

SYSUCC-001，。、、、、Ki-67、、。（DFS）。。Cox。

434（306128）。5DFS77.

，。

：Predict the benefit of metronomic capecitabine maintenance in early-stage triple-negative breast cancer: Results from the SYSUCC-001 study

：Predict the benefit of metronomic capecitabine maintenance in early-stage triple-negative breast cancer: Results from the SYSUCC-001 study：：Predict the benefit of metronomic capecitabine maintenance in early-stage triple-negative breast cancer: Results from the SYSUCC-001 study

GeparNuevo TNBC (NACT) durvalumab， PD-L1 (CPI)。Durvalumab (pCR) ， durvalumab （Loibl ，Ann Oncol 2019）。

GeparNuevo randomly assigned patients with cT1b-cT4a-d tumors and TNBC intensively diagnosed to durvalumab (D) 1.
5 g iv or placebo, once every 4 weeks.
D/placebo monotherapy (0.
75 g iv) was given for the first 2 weeks (window period), followed by D/placebo plus albumin-bound paclitaxel 125 mg/m² once a week for 12 weeks, followed by D/placebo Add epirubicin/cyclophosphamide (EC) q2 weeks for a total of 4 cycles.
Randomization was stratified by stromal tumor infiltrating lymphocytes (sTIL) (low (≤10%), medium (11-59%), high (≥60%)).
The main target is pCR (ypT0 ypN0).
The time endpoints of secondary events include aggressive disease-free survival (iDFS), distant disease-free survival (DDFS), and overall survival (OS).

Between June 2016 and September 2017, a total of 174 patients were enrolled in the group.
The pCR rate for durvalumab was 53.
4%, compared to 44.
2% for placebo (OR 1.
45, 95% CI 0.
80–2.
63, unadjusted Wald p = 0.
224).
The Durvalumab effect was only observed in the window cohort (pCR 61.
0% vs.
41.
4%, OR 2.
22, 95% CI 1.
06–4.
64, p = 0.
035; interaction p = 0.
048).
After a median follow-up of 42.
2 months, 34 events occurred in 174 patients.
The 3-year iDFS for pCR and non-pCR were 92.
0% and 71.
9%, respectively (log rank p = 0.
002).
The 3-year iDFS of durvalumab was 84.
9%, and the placebo was 76.
9% (HR 0.
54, 95% CI 0.
27-1.
09, stratified log-rank p = 0.
0559); 3-year DDFS 91.
4% and 79.
5% (HR 0.
37, 95% CI 0.
15-0.
87, p = 0.
0148); 3-year OS 95.
1% and 83.
1% (HR 0.
26, 95% CI 0.
09-0.
79, p = 0.
0076).
In iDFS, DDFS and OS, no differences were found between windowed and windowless queues.

Adding Durvalumab to the neoadjuvant chemotherapy of TNBC can significantly improve the long-term efficacy despite the small increase in pCR and no continuity after surgery.
What needs to be questioned is whether it is necessary to use CPI for adjuvant therapy.

For details, see: Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)

For details see: Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC) For details see: For details see:Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)

5.
The relationship between allograft rejection score and biological cancer aggressiveness and better survival rate with triple negative breast cancer (TNBC)

Although the importance of immunity in breast cancer progression has been widely reported, the clinical relevance of enhanced immune response remains unclear.
We hypothesize that an enhanced immune response is associated with better survival rates for breast cancer patients.

We used data from 6,245 breast cancer patients sample data from public data sets (METABRIC, GSE96058, TCGA cohort).
In order to clarify the function of immunity in breast cancer, we used the signature allogeneic rejection gene set to calculate the immune function score through the gene set variation analysis algorithm.

The immune response score was most correlated with the cytolytic activity of the iconic immune-related genomes in the two cohorts (Spearman rank correlation (r) was 0.
892 and 0.
860, respectively, both p <0.
01).
This score reflects the number of infiltrating immune cells, including several anti-cancer immune cells (CD8+ T cells, CD4+ memory T cells, type 1 helper T cells, M1 macrophages, plasmacytoid dendritic cells), type 2 helper T cells Cells and B cells.
The score is also related to the expression level of immune checkpoint molecular genes (all r> 0.
500).
High scores were significantly associated with high intratumoral heterogeneity, homologous recombination defects (HRD), and mutation rates in the TCGA cohort (all p<0.
001).
High scores are significantly related to late-stage Nottingham histological grade, late-stage and lymph node metastasis.
In ER-positive/HER2-negative breast cancer and TNBC, high-scoring breast cancer not only enriches the immune-related gene set, but also enriches the cancer-promoting-related gene set, such as epithelial-mesenchymal transition (EMT) and p53 pathway.
Compared with other subtypes, TNBC has the highest score, and TNBC with a higher score is significantly associated with a better survival rate.

The balance between malignant biology and enhanced immune response is an important factor in clinical outcome.

For details, see: Association of allograft rejection response score with biological cancer aggressiveness and with better survival in triple-negative breast cancer (TNBC)

For details see: For details see: For details see:Association of allograft rejection response score with biological cancer aggressiveness and with better survival in triple-negative breast cancer (TNBC)

This is a column that is being continuously updated, please pay attention to save this column~

This is a column that is being continuously updated, please pay attention to save and bookmark this column~ This is a column that is being continuously updated, please pay attention to save and bookmark this column~

For more information, follow the ASCO special page of Metz Medicine: https://meeting.
medsci.
cn/ASCO2020

https://meeting.
medsci.
cn/ASCO2020

Reference source: https://meetinglibrary.
asco.
org/results?meetingView=2021%20ASCO%20Annual%20Meeting

https://meetinglibrary.
asco.
org/results?meetingView=2021%20ASCO%20Annual%20Meeting Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.